← Back to Search

Mitotic Inhibitor

Treatment (mivavotinib and paclitaxel) for Ovarian Cancer

Phase 1
Waitlist Available
Led By Siqing Fu
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This study is evaluating whether a combination of two drugs may be more effective than either drug alone in treating patients with advanced solid tumors.

Eligible Conditions
  • Ovarian Cancer
  • Cancer
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To define the maximum tolerated doses (MTD) of TAK-659 and paclitaxel
Secondary outcome measures
Categorization of response based on Response Evaluation Criteria in Solid Tumors 1.1
Dose-limiting toxicity
Minimum detectable effect size

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (mivavotinib and paclitaxel)Experimental Treatment3 Interventions
Patients receive mivavotinib PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mivavotinib
2019
Completed Phase 1
~60
Paclitaxel
2011
Completed Phase 4
~5380

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,665 Previous Clinical Trials
40,925,802 Total Patients Enrolled
286 Trials studying Ovarian Cancer
73,766 Patients Enrolled for Ovarian Cancer
M.D. Anderson Cancer CenterLead Sponsor
2,973 Previous Clinical Trials
1,789,294 Total Patients Enrolled
47 Trials studying Ovarian Cancer
16,745 Patients Enrolled for Ovarian Cancer
Siqing FuPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
490 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
2019. "TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03756818.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top